Evotec's chief scientific officer Cord Dohrmann to step down September 30, 2026

Evotec SE announced on September 29, 2026 that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026. Evotec SE said Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, with a search ongoing for a successor.¹ The company said the decision for Dr. Dohrmann to step down was made by mutual consent between him and the company.¹

CEO Dr. Christian Wojczewski credited Dohrmann's tenure. Wojczewski thanked Dohrmann for his long service and many contributions to Evotec over the past 16 years, saying he had played a significant role in strengthening the company's scientific excellence and innovation culture.¹ Wojczewski also said Dohrmann helped establish key capabilities across Evotec's platforms, including its iPSC-based technologies and omics capabilities, which reinforced the company's scientific leadership.¹

In his own comments, Dohrmann reflected on changes in the drug development process over his time at the company. He said the process of advancing new therapies from discovery to the clinic has evolved significantly over the past 16 years, and that he was privileged to have contributed to that progress during his time at Evotec.¹

Dohrmann joined Evotec's leadership more than a decade and a half ago. He has held the roles of Chief Scientific Officer and Member of the Management Board since 2010.¹ Evotec said the search for his replacement is ongoing.¹

The announcement was filed as an exhibit to a Form 6-K submitted to the SEC on September 29, 2026, signed by CEO Christian Wojczewski.